Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

FDA, Industry Experts Highlight Key Regulatory Changes at DCAT Week ’16

What are the major regulatory changes impacting active pharmaceutical ingredient (API) manufacturing and what is the business impact for pharmaceutical companies and their suppliers?

From changes relating to starting materials, to topical GMP inspection concerns, such as data integrity, to the upcoming re-authorization of the Generic Drug User Fee Amendments (GDUFA), the DCAT Week ’16 education program, GDUFA II and GMP API Inspection Trends: The Business Impact of Upcoming Regulatory Changes,  provides insight from leading industry and regulatory experts on what should be on your radar.

The program, which will be held Tuesday March 15 from 1:00 to 3:30 PM, will feature a business impact debrief, provided by Frances Zipp, President & CEO, Lachman Consultants, who will provide a global regulatory debriefing on key recent and upcoming regulatory changes impacting active pharmaceutical ingredient (API) manufacturing and the pharmaceutical manufacturing value chain.

Plus, the US Food and Drug Administration (FDA) will provide a topical trend analysis for GMP inspections trends. Gain first-hand knowledge for the crucial issues drawing the attention of the agency in its inspection efforts in areas such as quality risk management, data integrity, and other concerns impacting API manufacturing.

In light of these issues, what are best practices that pharmaceutical companies, contract manufacturers, and suppliers can adapt to optimize external development and manufacturing? Robin Kumoluyi, Vice President & Global Head, Quality, Third Party Operations, Novartis Pharmaceuticals Corporation, offers perspective on best practices in supplier management and supplier oversight to help address these challenges.

Another key regulatory development ongoing in 2016 and coming to fruition in 2017 is the reauthorization of GDUFA. GDUFA is due for reauthorization in September 2017, and negotiations for GDUFA II are already underway. What has worked, what needs to be improved, and what changes may be on the horizon? Terri Nataline, J.D., Principal Consultant, Regulatory Practice, Lachman Consultants, provides the latest developments and what may be expected.

For information on this program, including how to register, may be found here.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

The Battle of the Blockbusters: GLP-1 Agonists

By
GLP-1 agonist drugs, in the form of Novo Nordisk’s Wegvoy/Ozempic, and Lilly’s Mounjaro for weight management and treating Type II diabetes, were blockbuster winners in 2023, putting this therapeutic sector into high focus. What has been the impact on manufacturing and what are other contenders in this high-growth sector?

Manufacturing & Supply Lines: Small-Molecule APIs

By
Small-molecule drugs still dominate new drug approvals, as measured by the number of new molecular entities approved by the FDA’s Center for Drug Evaluation and Research, but are they translating into market success? DCAT Value Chain Insights takes a look on the market for drugs with small-molecule active pharmaceutical ingredients and related supply–demand fundamentals.

European Parliament Takes Next Step in Reforming EU Pharma Legislation

By
The European Parliament adopted its positions on proposals to revamp the EU‘s pharmaceutical legislation, which includes measures impacting drug development, commercialization, manufacturing & the supply chain. European innovator & generic-drug companies weigh in.

What’s Trending: Generic Drugs by the Numbers & Key Market Developments

By
Generic-drug approvals in the US reached a recent high in 2023 although the number of first-generic approvals were down comparative to recent years. DCAT Value Chain Insights takes a look inside the numbers and the key market moves from the leading generic-drug companies.